JAMES M. FRATES - 12 Sep 2024 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Financial Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Issuer symbol
AMLX
Transactions as of
12 Sep 2024
Net transactions value
+$101,368
Form type
4
Filing time
16 Sep 2024, 17:30:37 UTC
Previous filing
11 Jun 2024
Next filing
06 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Purchase $101,368 +40,000 +21% $2.53 233,464 12 Sep 2024 Direct F1
holding AMLX Common Stock 15,459 12 Sep 2024 By Trust F2
holding AMLX Common Stock 11,072 12 Sep 2024 By Trust F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.4849 to $2.63. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
F2 Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F3 Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.